Terconazole

CHEMBL1714574 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
532.5 g/mol
LogP
4.8
Phase
4

Terconazole is a triazole antifungal agent that inhibits lanosterol 14α-demethylase (CYP51), a cytochrome P450 enzyme essential for ergosterol biosynthesis in fungal cell membranes, leading to membrane disruption and fungal cell death. It is available as a topical vaginal cream and suppository for the treatment of vulvovaginal candidiasis, including non-albicans Candida species. Its triazole structure provides enhanced antifungal potency compared to imidazole antifungals in the treatment of vaginal infections.

الوزن الجزيئي

532,5000 g/mol

LogP

4,80

TPSA

64,90 Ų

قاعدة ليبينسكي للخمسة

ناجح

آلية العمل

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1

InChI

InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3

Molecular Formula

C26H31Cl2N5O3

HBD / HBA

- / 7

الروابط القابلة للدوران

8

الذرات الثقيلة

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Terconazole is a triazole antifungal agent that inhibits lanosterol 14α-demethylase (CYP51), a cytochrome P450 enzyme essential for ergosterol biosynthesis in fungal cell membranes, leading to membrane disruption and fungal cell death. It is available as a topical vaginal cream and suppository for the treatment of vulvovaginal candidiasis, including non-albicans Candida species. Its triazole structure provides enhanced antifungal potency compared to imidazole antifungals in the treatment of vaginal infections.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Terconazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1714574. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 441383. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.